The triplet combination of azacitidine, venetoclax, and gilteritinib has also been evaluated in older adults and those unfit for intensive chemotherapy with newly diagnosed FLT3-mutated AML [58]. The gene discussed is FLT3; the disease is acute myeloid leukemia.